126 related articles for article (PubMed ID: 32888885)
41. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
[TBL] [Abstract][Full Text] [Related]
42. High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study.
Yoon JH; Kim HJ; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
J Hematol Oncol; 2017 Jan; 10(1):30. PubMed ID: 28114959
[TBL] [Abstract][Full Text] [Related]
43. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
[TBL] [Abstract][Full Text] [Related]
44. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A; Taki T; Koga D; Tabuchi K; Tawa A; Hanada R; Tsuchida M; Horibe K; Tsukimoto I; Adachi S; Kojima S; Hayashi Y
Int J Hematol; 2012 Oct; 96(4):469-76. PubMed ID: 22915059
[TBL] [Abstract][Full Text] [Related]
45. Prevalence and Prognostic Impact of Wilms' Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience.
Toogeh G; Ramzi M; Faranoush M; Amirizadeh N; Haghpanah S; Moghadam M; Cohan N
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e21-6. PubMed ID: 26725263
[TBL] [Abstract][Full Text] [Related]
46. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
[TBL] [Abstract][Full Text] [Related]
47. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
Weisser M; Kern W; Rauhut S; Schoch C; Hiddemann W; Haferlach T; Schnittger S
Leukemia; 2005 Aug; 19(8):1416-23. PubMed ID: 15920493
[TBL] [Abstract][Full Text] [Related]
48. The Role of Wilms' Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia.
Lazzarotto D; Candoni A
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743376
[TBL] [Abstract][Full Text] [Related]
49. Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
Duléry R; Nibourel O; Gauthier J; Elsermans V; Behal H; Coiteux V; Magro L; Renneville A; Marceau A; Boyer T; Quesnel B; Preudhomme C; Duhamel A; Yakoub-Agha I
Bone Marrow Transplant; 2017 Apr; 52(4):539-543. PubMed ID: 28067876
[TBL] [Abstract][Full Text] [Related]
50. Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies).
Bussaglia E; Pratcorona M; Carricondo M; Sansegundo L; Rubio MA; Monter A; Brell A; Badell I; Esteve J; Arnan M; Talarn C; Tormo M; García A; Vall-Llovera F; Ortin X; Pedro C; Bargay J; Brunet S; Sierra J; Nomdedéu J
Ann Hematol; 2020 Apr; 99(4):765-772. PubMed ID: 32062741
[TBL] [Abstract][Full Text] [Related]
51. Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation.
Rautenberg C; Pechtel S; Hildebrandt B; Betz B; Dienst A; Nachtkamp K; Kondakci M; Geyh S; Wieczorek D; Haas R; Germing U; Kobbe G; Schroeder T
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2337-2343. PubMed ID: 29753838
[TBL] [Abstract][Full Text] [Related]
52. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression.
Pozzi S; Geroldi S; Tedone E; Luchetti S; Grasso R; Colombo N; Di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Raiola AM; Dominietto A; Varaldo R; Signori A; Bacigalupo A
Br J Haematol; 2013 Feb; 160(4):503-9. PubMed ID: 23294252
[TBL] [Abstract][Full Text] [Related]
53. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
[TBL] [Abstract][Full Text] [Related]
54. [Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia].
Kim HR; Shin JH; Lee JN; Lee EY
Korean J Lab Med; 2007 Oct; 27(5):305-12. PubMed ID: 18094593
[TBL] [Abstract][Full Text] [Related]
55. Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia.
Nowakowska-Kopera A; Sacha T; Florek I; Zawada M; Czekalska S; Skotnicki AB
Leuk Lymphoma; 2009 Aug; 50(8):1326-32. PubMed ID: 19811333
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of diagnosed WT1 level in acute myeloid leukemia: a meta-analysis.
Yi-Ning Y; Xiao-rui W; Chu-xian Z; Chun W; You-wen Q
Ann Hematol; 2015 Jun; 94(6):929-38. PubMed ID: 25572170
[TBL] [Abstract][Full Text] [Related]
57. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
58. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
59. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.
Hou HA; Huang TC; Lin LI; Liu CY; Chen CY; Chou WC; Tang JL; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Blood; 2010 Jun; 115(25):5222-31. PubMed ID: 20368469
[TBL] [Abstract][Full Text] [Related]
60. The association of level of reduction of Wilms' tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients.
Shibasaki Y; Seki Y; Tanaka T; Miyakoshi S; Fuse K; Kozakai T; Kobayashi H; Ushiki T; Abe T; Yano T; Moriyama M; Kuroha T; Isahai N; Takizawa J; Narita M; Koyama S; Furukawa T; Sone H; Masuko M
Leuk Res; 2015 Jun; 39(6):667-71. PubMed ID: 25890432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
